Hemispherx BioPharma, Inc. Press Releases

HEB 
$0.2972
*  
0.0072
2.48%
Get HEB Alerts
*Delayed - data as of Jul. 11, 2014  -  Find a broker to begin trading HEB now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
7/8/2014 8:30:00 AM - GlobeNewswire

Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26
6/25/2014 8:30:00 AM - GlobeNewswire

Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
6/16/2014 8:30:00 AM - GlobeNewswire

Biotech Equities Technical Analysis -- Research on Hemispherx Biopharma, Intercept Pharma, MiMedx, and Raptor Pharma
6/13/2014 8:10:00 AM - PR Newswire

Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
6/3/2014 1:06:00 PM - GlobeNewswire

Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations
5/27/2014 9:26:00 AM - GlobeNewswire

Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
5/21/2014 8:30:00 AM - GlobeNewswire

Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains
5/14/2014 8:30:00 AM - GlobeNewswire

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014
5/9/2014 4:15:00 PM - GlobeNewswire

Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
5/8/2014 2:30:00 PM - PR Newswire

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro
5/5/2014 8:30:00 AM - GlobeNewswire